Advisor Group’s ImmunityBio IBRX Stock Holding History

Advisor Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$7K	Buy	1,803 +1,188	+193%	+$2.02K	﹤0.01%	4517
2019 Q3	$1K	Hold	615	–	–	﹤0.01%	5121
2019 Q2	$1K	Hold	615	–	–	﹤0.01%	5110
2019 Q1	$1K	Hold	615	–	–	﹤0.01%	5075
2018 Q4	$1K	Buy	615 +198	+47%	+$453	﹤0.01%	4969
2018 Q3	$2K	Hold	417	–	–	﹤0.01%	4854
2018 Q2	$1K	Buy	417 +161	+63%	+$596	﹤0.01%	4796
2018 Q1	$1K	Hold	256	–	–	﹤0.01%	4815
2017 Q4	$1K	Buy	+256	New	+$1.21K	﹤0.01%	4823

Other funds holding IBRX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Advisor Group's IBRX Position: Q4 2019 in Review

Advisor Group increased its ImmunityBio (IBRX) stake by 193% in Q4 2019, buying an estimated $2.02K and bringing the position to 1,803 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #4517.

Advisor Group first reported a position in IBRX in Q4 2017 and has held it in 9 quarters since. 47 funds tracked by Wall St. Rank hold IBRX as of Q4 2019.

Advisor Group held 1,803 shares of ImmunityBio worth $7K as of Q4 2019.
Advisor Group bought 1,188 ImmunityBio shares in Q4 2019, an estimated $2.02K.
ImmunityBio made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4517 holding.
Advisor Group first reported a position in ImmunityBio in Q4 2017 and has held it in 9 quarters since.
47 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.